Thermo Fisher Scientific: Will Its Shift Toward Contract Research and Manufacturing Pay Off?

For the fourth quarter of 2024, Thermo Fisher Scientific reported a 5% year-over-year growth in revenue, reaching $11.4 billion, alongside a 7% increase in adjusted operating income, which totaled $2.72 billion. This resulted in an adjusted operating margin expansion by 50 basis points to 23.9%. Moreover, adjusted earnings per share (EPS) grew by 8% to $6.10. For the full year, revenue amounted to $42.9 billion, indicating stability in the face of ongoing market challenges.